Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients
✍ Scribed by P. E. Wallemacq; V. Furlan; A. Möller; A. Schäfer; P. Stadler; I. Firdaous; A -M. Taburet; R. Reding; S. Clement De Clety; J. De Ville De Goyet; E. Sokal; L. Lykavieris; V. Van Leeuw; O. Bernard; J. B. Otte; N. A. Undre
- Publisher
- Springer-Verlag
- Year
- 1998
- Tongue
- English
- Weight
- 410 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0378-7966
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Lymphoproliferative disorders (LPDs) are a serious side effect of immunosuppression after liver transplantation, and the introduction on the market of a new immunosuppressive drug has been associated with an increased risk of these disorders. To compare the effect of cyclosporine A (CSA) and FK506 i
## Pharmacokinetics of tacrolimus in liver transplant patients O&e&ve,e: To characterize the pharmacokinetics of the immunosuppressive agent tacrolimus (IX 506) in liver transplant patients. Metboh: Patients (n = 16) were assessed during and after l-to 3&y intravenous infusions followed by a 2-wee
Hypertension frequently develops early after liver transplantation when cyclosporine-based immunosuppression is used. However, initial experience with tacrolimus has suggested that its use leads to a lower early incidence of hypertension. In this study, the blood pressure status of patients treated